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Background: Glycated albumin (GA) has been reported to be a better indicator of glycemic control than
hemoglobin A1c (HbA1c) in diabetic hemodialysis (HD) patients.
Methods: We performed a cross-sectional study to evaluate associations between daily glucose profiles based on
blood glucose measurements at seven different times a day and their GA, HbA1c, and pre-dialysis glucose levels in
90 HD patients with (n = 46) and without (n = 44) diabetes.
Results: The results of a univariate analysis showed that the GA, HbA1c, and pre-dialaysis glucose levels were
significantly correlated with the daily glucose profiles. In a multivariate analysis, the GA levels were found to be
independently correlated with maximum glucose levels (F = 9.448, P = 0.0028) and mean amplitude of glucose
excursion (MAGE, F = 5.169, P = 0.0255), but no significant correlation was found between the HbA1c levels and
daily glucose profiles. The pre-dialysis glucose levels were independently correlated with minimum glucose levels
(F = 8.336, P = 0.0049). In a stratified analysis, the identical trend was seen in the diabetic HD patients, but an
independent correlation was found only between HbA1c values and mean glucose levels in nondiabetic HD patients.
Conclusions: GA levels may be a better indicator of glycemic control than HbA1c and pre-dialysis glucose levels,
especially as a means of evaluating the glucose excursions in diabetic HD patients.
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Diabetes mellitus is the leading cause of chronic kidney
disease and of being started on hemodialysis (HD) [1],
and it is associated with cardiovascular disease that rep-
resents a common risk of morbidity and mortality in HD
patients [2]. Hyperglycemia causes micro- and macroan-
giopathy in diabetic patients, and better glycemic control
prevents diabetic complications [3, 4]. However, observa-
tional studies that have evaluated the relationship between
glycemic control and the survival of HD patients with dia-
betes have yielded conflicting results [5–7]. Using serum
glycated hemoglobin (HbA1c) to assess glycemic control
in HD patients may result in underestimation of the level* Correspondence: nitta@kc.twmu.ac.jp
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(http://creativecommons.org/publicdomain/zeof glycemic control, because the life span of the red blood
cells of HD patients is shorter, because the percentage of
immature red blood cells is increased by erythropoiesis-
stimulating agent therapy, and because blood loss may
occur during HD therapy [8]. Previous studies have shown
that glycated albumin (GA), whose levels are unaffected
by the life-span of red blood cells, may be a better indi-
cator of glycemic control in HD patients than HbA1c
[9, 10]. The Japanese Society for Dialysis Therapy rec-
ommends pre-dialysis glucose levels and GA levels as
better indicators of glycemic control than HbA1c in dia-
betic HD patients [11]. However, these studies used only
casual blood glucose levels as the gold standard for
comparison with HbA1c and GA levels.
The glucose excursions have been shown to increase
the risk of diabetic macroangiopathy [4, 12]. GA levelsis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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cemic control, especially as a means of evaluating post-
prandial glycemic excursion than HbA1c in diabetic
patients without nephropathy [13]. The aim of this study
was to investigate associations between the pre-dialysis
glucose, HbA1c, GA levels of HD patients, and their
daily glucose profiles.
Methods
Subjects
We performed a cross-sectional study of 90 HD patients
who had been admitted to Shinjuku Ishikawa Hospital.
Patients who had inflammatory disease, gastrointestinal
hemorrhage, or malignant disease were excluded. Pa-
tients capable of an oral diet were included in this study,
and they were mostly admitted because of vascular ac-
cess trouble and social problem. The glucose-lowering
therapy of the subjects had been unchanged for at least
3 months prior to enroll into this study.
After a full explanation of this study, written informed
consent was obtained from each patient. The study was
performed in accordance with the Declaration of Helsinki
and the Principles of Good Clinical Practice, and the
Institutional Research Ethics Committee approved the
study protocol.
Biochemical measurements
All blood samples for biochemical measurements were
collected before the first HD session after hospital ad-
mission. HbA1c, GA, and the other parameters were
measured at reference laboratories (SRL Inc., Tokyo,
Japan). The daily glucose profile was based on measure-
ments made by medical staff before and 2 h after each
meal and at bedtime, and the data was used to calculate
the mean, minimum (Min), maximum (Max) glucoseTable 1 Baseline demographic data and clinical characteristics of th
All patients (n = 90) D
Age (years) 68.8 ± 12.1 6
Gender (male) 66.6 7
Hemodialysis vintage (months) 115.8 ± 166.1 1
Body mass index (kg/m2) 21.2 ± 3.9 2
Hemoglobin (g/dl) 9.9 ± 1.4 1
Albumin (g/dl) 3.3 ± 0.4 3
Blood urea nitrogen (mg/dl) 60.1 ± 17.8 6
Creatinine (mg/dl) 9.7 ± 3.1 9
Diabetes (%) 51.1 1
Oral hypoglycemic agent (%) 14.4 2
Insulin (%) 13.3 2
Erythropoiesis-stimulating agents (IU/week) 5270.8 ± 4186.5 5
Variables are presented as mean ± SD
aDiabetic patients vs nondiabetic patientslevels, and the mean amplitude of glucose excursion
(MAGE) [14].
Statistical analysis
Continuous variables are reported as the mean ± SD, and
categorical variables are reported as percentages unless
otherwise stated. The relationships among continuous
variables were analyzed by the Pearson correlation test. A
multiple linear regression analysis was performed to
evaluate the relationships among glycated protein levels
and various parameters of the daily glucose profile. P
values less than 0.05 were considered to indicate statistical
significance. All analyses were performed with the JMP for
Windows software program (SAS Institute, Cary, NC,
USA).
Results
A total of 90 HD patients were enrolled in this study.
Their baseline characteristics, including laboratory data,
are shown in Table 1. The mean age of the subjects was
68.8 ± 12.1 years, and their mean HD vintage was 115.8
± 166.1 months. The patients who were started on HD
therapy because of diabetic nephropathy accounted for
43.3 %, and patients diagnosed with type 2 diabetes
accounted for 51.1 %. The baseline characteristics of the
diabetic and nondiabetic HD patients are also shown in
Table 1. Whereas the serum creatinine levels were sig-
nificantly lower in the diabetic HD patients, the BMI
and blood urea nitrogen levels tended to be higher but
did not reach statistical significance. Oral hypoglycemic
agents were being used to treat 28.3 % of the diabetic
HD patients, and 26 % were on insulin therapy. Their
glycemic parameters, including the Min, mean, Max glu-
cose levels, Max-Min glucose levels, and MAGE values
are shown in Table 2. All parameters, particularly thee enrolled hemodialysis patients
iabetic patients (n = 46) Nondiabetic patients (n = 44) P valuea
6.3 ± 11.4 71.3 ± 12.5 0.0536
3.9 59.1 0.135
02.4 ± 194.9 129.4 ± 131.2 0.447
2.0 ± 4.4 20.4 ± 3.1 0.0596
0.2 ± 1.4 9.6 ± 1.5 0.062
.3 ± 0.4 3.3 ± 0.4 0.7119
2.1 ± 18.7 58.0 ± 16.8 0.2767
.1 ± 3.0 10.4 ± 3.2 0.0480
00 0 <0.0001
8.3 0 <0.0001
6.1 0 <0.0001
225.5 ± 4428.9 5318.2 ± 3968.0 0.9171
Table 2 Glycemic control parameters among the enrolled hemodialysis patients
All patients (n = 90) Diabetic patients (n = 46) Nondiabetic patients (n = 44) P valuea
Min glucose (mg/dl) 109.1 ± 31.3 120.5 ± 34.7 97.2 ± 22.0 <0.001
Mean glucose (mg/dl) 152.3 ± 38.6 175.5 ± 38.6 128.0 ± 18.2 <0.001
Max glucose (mg/dl) 203.4 ± 62.0 241.9 ± 61.2 163.2 ± 28.3 <0.001
Max-Min glucose (mg/dl) 100.3 ± 58.9 130.6 ± 64.9 68.7 ± 27.8 <0.001
MAGE 66.8 ± 38.3 85.4 ± 42.1 47.4 ± 20.7 <0.001
Pre-dialysis glucose (mg/dl) 144.6 ± 49.6 165.2 ± 56.3 123.2 ± 29.1 <0.001
HbA1c (%) 5.4 ± 0.9 5.8 ± 1.1 4.9 ± 0.5 <0.001
GA (%) 19.1 ± 4.7 21.9 ± 4.7 16.1 ± 2.4 <0.001
Variables are presented as mean ± SD
Min minimum, Max maximum, MAGE mean amplitude of glucose excursion, HbA1c hemoglobin A1c, GA glycated albumin
aDiabetic patients vs nondiabetic patients
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the diabetic HD patients. The pre-dialysis glucose levels
were close with the mean glucose levels.
Glycated albumin, HbA1c, and pre-dialysis glucose levels
in all patients
The GA values, HbA1c values, and pre-dialysis glucose
levels of the subjects as a whole were correlated with
their daily glucose profiles (Table 3).
The GA levels, HbA1c levels, and pre-dialysis glucose
levels of the subjects as a whole were correlated with
their daily glucose profiles (Table 3). In univariate ana-
lysis, the HbA1c values were strongly correlated withTable 3 Association between the indicators of glycemic control and
with and without diabetes
All patients (n = 90)
Factors Parameters Univariate Mul
R2 P F
GA (%) Min glucose (mg/dl) 0.216 <0.0001 0.91
Mean glucose (mg/dl) 0.532 <0.0001 2.66
Max glucose (mg/dl) 0.511 <0.0001 9.44
MAGE 0.286 <0.0001 5.16
Max-Min glucose (mg/dl) 0.323 <0.0001
HbA1c (%) Min glucose (mg/dl) 0.363 <0.0001 2.72
Mean glucose (mg/dl) 0.501 <0.0001 3.75
Max glucose (mg/dl) 0.393 <0.0001 2.95
MAGE 0.171 <0.0001 2.81
Max-Min glucose (mg/dl) 0.169 <0.0001
Pre-dialysis glucose (mg/dl) Min glucose (mg/dl) 0.363 <0.0001 8.33
Mean glucose (mg/dl) 0.376 <0.0001 0.95
Max glucose (mg/dl) 0.312 <0.0001 0.80
MAGE 0.147 0.0002 0.25
Max-Min glucose (mg/dl) 0.142 0.0003
Pearson correlation test was performed for univariate analysis. Multiple linear regre
GA glycated albumin, HbA1c hemoglobin A1c, MAGE mean amplitude of glucose exthe mean glucose levels as a whole. The pre-dialysis glu-
cose levels were also significantly correlated with the
Min and mean glucose levels. The GA values, on the
other hand, were strongly correlated with the Max glu-
cose levels as well as with the mean glucose levels.
Accordingly to the multivariate analysis, the GA values
were independently correlated with the Max glucose
levels and MAGE values, and the strongest correlation
was found between the GA values and Max glucose
levels, but a significant correlation was not found be-
tween the HbA1c values and daily glucose profiles. The
pre-dialysis glucose levels were independently correlated
with the Min glucose levels.parameters of daily glucose profiles in hemodialysis patients
Diabetic patients (n = 46) Non diabetic patients (n = 44)
tivariate Univariate Multivariate Univariate Multivariate
P R2 P F P R2 P F P
7 0.341 0.174 0.004 1.167 0.2863 0.000 0.941 0.459 0.502
5 0.1063 0.385 <0.0001 1.334 0.2548 0.098 0.0383 0.848 0.3627
8 0.0028 0.329 <0.0001 7.906 0.0075 0.122 0.0201 0.012 0.9152
9 0.0255 0.111 0.0235 6.349 0.0157 0.114 0.0253 0.821 0.3705
0.136 0.0118 0.124 0.0192
6 0.1024 0.385 <0.0001 1.849 0.1814 0.027 0.2861 0.0018 0.9664
1 0.0561 0.363 <0.0001 0.636 0.4299 0.274 0.0003 8.259 0.0066
7 0.0892 0.226 0.0008 2.995 0.0910 0.181 0.0040 1.898 0.1761
7 0.0970 0.038 0.1918 2.959 0.0930 0.122 0.0200 2.889 0.0972
0.032 0.2334 0.118 0.0223
6 0.0049 0.435 <0.0001 9.730 0.0033 0.014 0.4449 0.043 0.8366
0 0.3324 0.262 0.0003 0.012 0.9150 0.168 0.0058 1.198 0.2804
2 0.3729 0.167 0.0049 0.139 0.7114 0.182 0.0039 0.001 0.9724
9 0.6124 0.034 0.2190 0.009 0.9266 0.127 0.0174 0.531 0.4705
0.027 0.2773 0.132 0.0153
ssion analysis was performed for multivariate analysis
cursion
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Fig. 1 Correlation between the glycated albumin (GA) and
hemoglobin A1c (HbA1c) levels of diabetic (black squares) and
nondiabetic (white squares) hemodialysis patients
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As shown in Fig. 1, the GA values of the diabetic HD pa-
tients were correlated with their HbA1c values (r = 0.697,
P < 0.0001), but not of the nondiabetic HD patients
(r = 0.252, P = 0.0984). The GA/HbA1c ratio was 3.1
in the diabetic HD patients.
The relationship of each indicator of glucose control
and the Min, mean, Max glucose levels, and MAGE
values of diabetic and nondiabetic HD patients is also
shown in Table 3. The GA values, HbA1c values, and
pre-dialysis glucose levels were correlated with the daily
glucose profile in diabetic patients similar in all subjects.
The identical trend was seen in multivariate analysis that
the independently correlation was found in the GA
values with Max glucose levels and MAGE values, which
show the glucose excursion, and pre-dialysis glucose
levels with the Min glucose levels. In contrast, the cor-
relation of daily glucose profiles and GA values was
weaker than the correlation between the HbA1c values
and pre-dialysis glucose levels in nondiabetic HD pa-
tients. The results of the multivariate analysis did not
show any independent correlation between the GA
values, pre-dialysis glucose levels, and their daily glucose
profiles in nondiabetic HD patients. On the other hand,
the HbA1c values were independently correlated with
the mean glucose levels in nondiabetic HD patients.Discussion
The results of this study showed significant correlations
between the pre-dialysis glucose, HbA1c values, and GA
values and their daily glucose profiles in HD patients.
They also showed that only the GA levels were inde-
pendently correlated with the glucose excursions.
Since the lifespan of erythrocytes is approximately
120 days, serum HbA1c levels reflect blood glucose
levels over the preceding several months. GA levels areused as an indicator of short-term glycemic control, be-
cause metabolic albumin turnover is faster than
hemoglobin turnover; albumin has a lifespan of approxi-
mately 17 to 23 days. Furthermore, large blood glucose
fluctuation could enhance the glycation and oxidation
reaction of albumin, followed by increases in GA levels.
Moreover, hyperglycemia has been reported to reduce
erythrocyte survival [15]. Since diabetic HD patients have
many factors that affect their serum HbA1c levels, their
GA levels were better indicator of glycemic control, espe-
cially of the glucose excursions than HbA1c in HD patients
who have a large glucose fluctuation. We did not find a cor-
relation between hemoglobin, ESA use and HbA1c, serum
albumin and GA that have been reported by previous stud-
ies [9, 10]. However, the GA/HbA1c ratio in the present
study was higher than reported in a previous study [13].
A large cohort study of 1484 HD patients reported
finding that poor glycemic control of maintenance HD
patients was not associated with their mortality [7]. This
study used casual glucose and HbA1c levels as the indi-
cator of glycemic control, and this cohort included non-
diabetic HD patients, and their HbA1c levels were
generally low. The GA, HbA1c, and pre-dialysis glucose
levels in our study were not correlated with their glucose
excursions of nondiabetic HD patients. One of the po-
tential reasons for this finding is that the glucose levels
in nondiabetic HD patients fluctuated within a narrow
range. The results of other studies that investigated the
impact of HbA1c on the survival of HD patients
showed only extremely high or low HbA1c levels were
associated with longer survival [5, 6]. Thus, the opti-
mal target glycemic control to improve the survival of
diabetic HD patients is still unknown [16]. It is well
known that postprandial hyperglycemia in diabetic pa-
tients is associated with the progression of diabetic
macroangiopathy [17, 18]. Our data showed that GA
levels were a better indicator of the glucose fluctua-
tions. A few recent studies have reported finding that
high GA levels were associated with increased mortal-
ity in diabetic HD patients [19, 20].
Our study had several limitations. First, only hospital-
ized patients were enrolled as subjects. The hospital diet
provided 30–35 kcal/kg/day, and since it may have dif-
fered from the subjects’ usual diet, the difference may
have affected their daily glycemic profiles. Second, the
daily glucose profiles were based on a seven-point blood
glucose measurement a day, and a continuous glucose-
monitoring system, which provides continuous detailed
records of glucose levels, may have provided more ac-
curate information.
Conclusions
HbA1c and pre-dialysis glucose levels were affected by
the daily glucose profiles in diabetic HD patients. The
Tsuruta et al. Renal Replacement Therapy  (2016) 2:3 Page 5 of 5GA levels could be a better indicator of glycemic control
than HbA1c and pre-dialysis glucose levels, because
serum GA levels may reflect the glucose excursion.
These results warrant further trials to assess the useful-
ness of GA levels as an indicator of diabetic complica-
tions and mortality in diabetic HD patients.
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